Rockwell Medical, Inc. (DE) Common Stock (RMTI)

Price$0.66

Value ScoreB

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-41.16%

Price vs S&P 500 (4W)-20.30%

VGM Score43.91

Market Capitalization$26.23M

All Metrics

P/CF (Annual)8.97x

Book Value / Share (Quarterly)$0.91

P/TBV (Annual)1.20x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-1.65%

Cash Flow / Share (Quarterly)$0.04

Price vs S&P 500 (YTD)-28.43%

Gross Margin (TTM)18.10%

Net Profit Margin (TTM)-7.98%

EPS (TTM)$-0.15

10-Day Avg Trading Volume0.39M

EPS Excl Extra (TTM)$-0.15

Revenue Growth (5Y)2.17%

EPS (Annual)$-0.15

ROI (Annual)-11.34%

Gross Margin (Annual)18.62%

Net Profit Margin (5Y Avg)-19.33%

Cash / Share (Quarterly)$0.61

Revenue Growth QoQ (YoY)-8.34%

ROA (Last FY)-9.30%

Revenue Growth TTM (YoY)-30.75%

EBITD / Share (TTM)$-0.07

ROE (5Y Avg)-294.82%

Operating Margin (TTM)-7.11%

Cash Flow / Share (Annual)$-0.03

P/B Ratio0.73x

P/B Ratio (Quarterly)0.98x

Net Income / Employee (Annual)$-33,800

EV / Revenue (TTM)0.39x

Net Interest Coverage (TTM)-7.53x

ROA (TTM)-9.62%

EV / EBITDA (TTM)29.30x

EPS Incl Extra (Annual)$-0.15

Current Ratio (Annual)3.98x

Quick Ratio (Quarterly)3.32x

3-Month Avg Trading Volume0.28M

52-Week Price Return-31.92%

EV / Free Cash Flow (Annual)10.71x

Revenue / Employee (TTM)$431,100

Tangible BV / Share (Quarterly)$0.67

P/S Ratio (Annual)0.38x

Asset Turnover (Annual)1.21x

52-Week High$2.10

Operating Margin (5Y Avg)-17.24%

EPS Excl Extra (Annual)$-0.15

CapEx CAGR (5Y)-12.39%

Tangible BV CAGR (5Y)-3.65%

26-Week Price Return-33.24%

Quick Ratio (Annual)3.46x

13-Week Price Return-25.35%

Total Debt / Equity (Annual)0.27x

Current Ratio (Quarterly)3.74x

Enterprise Value$26.26M

Revenue / Share Growth (5Y)-26.63%

Asset Turnover (TTM)1.20x

Book Value / Share Growth (5Y)-25.23%

Revenue / Employee (Annual)$441,100

Inventory Turnover (Annual)12.25x

Pretax Margin (Annual)-7.67%

Cash / Share (Annual)$0.63

3-Month Return Std Dev56.00%

Gross Margin (5Y Avg)9.59%

Net Income / Employee (TTM)$-34,400

ROE (Last FY)-14.37%

Net Interest Coverage (Annual)-8.11x

EPS Basic Excl Extra (Annual)$-0.15

P/FCF (TTM)6.75x

Receivables Turnover (TTM)7.32x

EV / Free Cash Flow (TTM)14.94x

Total Debt / Equity (Quarterly)0.27x

EPS Incl Extra (TTM)$-0.15

Receivables Turnover (Annual)8.43x

ROI (TTM)-11.98%

P/S Ratio (TTM)0.39x

Pretax Margin (5Y Avg)-19.33%

Revenue / Share (Annual)$1.93

Tangible BV / Share (Annual)$0.69

Price vs S&P 500 (52W)-56.28%

Year-to-Date Return-20.28%

5-Day Price Return-7.48%

EPS Normalized (Annual)$-0.15

ROA (5Y Avg)-26.72%

Net Profit Margin (Annual)-7.67%

Month-to-Date Return-10.63%

Cash Flow / Share (TTM)$-0.70

EBITD / Share (Annual)$-0.07

Operating Margin (Annual)-6.77%

LT Debt / Equity (Annual)0.24x

P/CF (TTM)9.86x

ROI (5Y Avg)-51.24%

LT Debt / Equity (Quarterly)0.23x

EPS Basic Excl Extra (TTM)$-0.15

P/TBV (Quarterly)1.34x

P/B Ratio (Annual)0.89x

Inventory Turnover (TTM)13.69x

Pretax Margin (TTM)-7.98%

Book Value / Share (Annual)$0.94

Price vs S&P 500 (13W)-33.60%

Beta1.60x

P/FCF (Annual)8.22x

Revenue / Share (TTM)$1.72

ROE (TTM)-15.41%

52-Week Low$0.64

vGradeB

gGradeD

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.04est. -0.03

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RMTIRockwell Medical, Inc. (DE) Common Stock	B	D	D	$0.66
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Rockwell Medical Inc manufactures and distributes dialysis concentrates—essential consumables used in hemodialysis treatment. The company supplies liquid and dry bicarbonate and acid formulations, including CitraPure, RenalPure, and SteriLyte, to dialysis providers across the United States. It operates in a stable, recurring-revenue market driven by the ongoing treatment needs of dialysis patients.